Hilma Biocare Tirzepatide 10 mg

Hilma Biocare Tirzepatide 10 mg — Weight loss & metabolic control

Hilma Biocare Tirzepatide 10 mg is a dual GIP/GLP-1 receptor agonist designed to promote weight loss and improve blood sugar control. It works similarly to Mounjaro and is administered as a weekly subcutaneous injection.

What it does

Tirzepatide enhances insulin release, suppresses glucagon, reduces your appetite, and increases feelings of fullness — all of which drive weight loss and improve your metabolic markers like blood sugar and cholesterol.

How to use it

• Dosing schedule: Start at 2.5 mg once weekly, then increase by 2.5 mg every 4 weeks (5 mg, then 7.5 mg, then 10 mg). You may continue to 12.5–15 mg weekly if needed and tolerated.
• Duration: Typically 12–24 weeks or longer depending on your results.
• Administration: Inject under the skin once per week using sterile technique; follow storage instructions.

Getting the best results

Tirzepatide works best when combined with healthy eating and regular exercise. Eat smaller meals and stay well hydrated, especially during the first few weeks when your body is adjusting. Gradual dose increases help minimize nausea and other digestive side effects.

Side effects to expect

Common: Nausea, vomiting, diarrhea, constipation, and decreased appetite — most improve as your body adjusts.

Serious (rare): Severe abdominal pain, persistent vomiting, pancreatitis, gallbladder problems, or signs of allergic reaction. Stop use immediately if you experience any of these.

Important safety information

Do not use if you are pregnant or breastfeeding. Use caution if you have a personal or family history of thyroid cancer or MEN2 syndrome. Be aware of potential interactions with other medications and existing health conditions. Stay hydrated to avoid kidney problems from severe vomiting or dehydration.

We recommend using our peptide dosage & reconstitution calculators.